Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: a Retrospective Cohort Study

ConclusionsYounger age, normal renal function, and nonadherence to the dosing protocol when targeting therapeutic anticoagulation is associated with increased risk of failure to achieve ETA. This confers an elevated risk of thromboembolism when using bivalirudin for the management of HIT or other coagulation disorders.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 5, 2019 Category: Drugs & Pharmacology Authors: Libby A Orzel, Erik E. Abel, Danielle M. Blais, Tzu ‐Fei Wang, Kyle A Porter, Pamela K. Burcham Tags: ORIGINAL RESEARCH ARTICLE Source Type: research